ArticleFrontiers in medicine2025
Dendritic fibromyxolipoma of the male breast: case report and literary review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dendritic fibromyxolipoma (DFML) represents a benign lipomatous tumor. Its rarity and distinctive morphology can lead to misinterpretation of other mesenchymal malignancies, which may result in unnecessary aggressive treatments. Case presentation: A 39-year-old male presented with a left mammary mass that had been noticed 1 year earlier. Chest computed tomography identified a nodule characterized by fat density in the left mammary region. The initial clinical impression was gynecomastia. A local excision of the left mammary mass was subsequently performed. Histopathological analysis confirmed the diagnosis of DFML. Post-surgical follow-up over 38 months showed no recurrence. Conclusion: DFML is a benign lipomatous tumor with unique morphological features. Complete surgical excision typically leads to no recurrence. This report documents the first known instance of DFML in the mammary gland of a male patient. Furthermore, an analysis of 95 previously documented cases of DFML was conducted. It is strongly advocated that the World Health Organization reclassify DFML as a mucinous subtype of spindle cell lipoma. This reclassification would improve the understanding of DFML and help avoid unnecessary aggressive treatments due to misdiagnosis as a malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.